Quest Diagnostics INC Form 4 insider transactions

Quest Diagnostics Executive Vice President and CFO Sam Samad acquired common stock through a performance award settlement and disposed of shares for tax withholding.

Catherine T. Doherty, EVP of Regional Businesses at Quest Diagnostics, reported the acquisition of shares from a performance award, subsequent tax-related dispositions, and a sale under a 10b5-1 plan.

Quest Diagnostics SVP & Chief Commercial Officer Mark E. Delaney received a performance stock award and subsequently sold shares to cover tax obligations.

Quest Diagnostics' SVP & General Counsel, Michael E. Prevoznik, reported the acquisition of shares from a performance award and subsequent sales for tax obligations and a pre-planned 10b5-1 plan.

Quest Diagnostics CEO and President, J. E. Davis, acquired 51,652 shares from a performance stock award and subsequently disposed of 26,414 shares for tax withholding.

Quest Diagnostics SVP Patrick Plewman reported the settlement of a performance stock award, subsequent tax withholding, and a planned sale of common stock.

Quest Diagnostics' SVP, Corporate Controller & CAO, Michael J. Deppe, increased his direct ownership of company common stock through a performance award settlement.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, increased direct ownership of company common stock following a performance award settlement.

Quest Diagnostics' EVP of Regional Businesses, Catherine T. Doherty, reported sales of common stock totaling 1,280 shares for tax obligations and pursuant to a 10b5-1 plan.

Quest Diagnostics' Executive Vice President and CFO, Sam Samad, sold 869 shares of common stock to cover tax liabilities from restricted share unit vesting.

Quest Diagnostics' SVP & General Counsel, Michael E. Prevoznik, reported routine sales of common stock, including tax-related dispositions and sales under a 10b5-1 plan.

Quest Diagnostics CEO and President J. E. Davis sold a total of 12,968 shares of common stock on March 2, 2026, including sales for tax obligations and under a 10b5-1 plan.

Quest Diagnostics SVP Patrick Plewman reported sales of company common stock totaling 640 shares through tax-related and pre-planned transactions.

Quest Diagnostics' SVP of Clinical Solutions, Karthik Kuppusamy, reported a sale of 205 common shares to cover tax liabilities from restricted stock unit vesting.

Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics, sold 188 shares of common stock to cover tax obligations from restricted share unit vesting.

Quest Diagnostics SVP Michael J. Deppe sold 88 shares of common stock to cover tax liabilities from restricted share unit vesting.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, reported the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Quest Diagnostics CEO and President J. E. Davis exercised stock options and subsequently sold 55,093 shares of common stock under a pre-arranged Rule 10b5-1 plan.

Quest Diagnostics Director Vicky B. Gregg reported the sale of 1,250 shares of common stock at $191.76 per share under a pre-planned trading arrangement.

Quest Diagnostics' SVP & Chief Commercial Officer, Mark E. Delaney, sold 7,946 shares of common stock for $187.35 per share after exercising options, as part of a pre-arranged 10b5-1 plan.

Quest Diagnostics CEO and President J. E. Davis disposed of 7,143 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Quest Diagnostics' Executive Vice President and CFO, Sam Samad, acquired 68 shares of common stock through a dividend reinvestment plan.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, acquired 46 shares of common stock through a dividend reinvestment plan.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reported the acquisition of 15 shares of common stock through a dividend reinvestment plan.

Quest Diagnostics Director Gary M. Pfeiffer sold 1,482 shares of common stock and transferred phantom stock units.

Vicky B. Gregg, a director at Quest Diagnostics Inc., acquired 70 shares of common stock through a dividend reinvestment plan at $189.082 per share.

Quest Diagnostics SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock through a dividend reinvestment plan.

Quest Diagnostics Director Robert B. Carter acquired 6 shares of common stock through a dividend reinvestment plan.

Quest Diagnostics director Timothy M. Ring acquired 233 phantom stock units through an elective deferral of cash compensation.

A Quest Diagnostics director acquired phantom stock units through an elective deferral of cash compensation.